Parnell Launches Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution for Dogs

News > Health News

Audio By Carbonatix

9:11 AM on Tuesday, March 3

The Associated Press

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Mar 3, 2026--

Parnell today announced the launch of Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution, a Class III controlled veterinary product formulated for humane, painless, and rapid euthanasia of dogs, available in 100 mL multi‑dose vials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303495750/en/

Parnell Pentobarbital Sodium and Phenytoin Sodium

Designed for clinical reliability and ease of identification in practice settings, Parnell’s formulation contains 390 mg/mL pentobarbital sodium and 50 mg/mL phenytoin sodium, with Rhodamine B (bluish‑red dye) to clearly distinguish it from parenteral drugs intended for therapeutic use.

“At Parnell, we understand the responsibility veterinarians carry during end‑of‑life care,” said Pablo Lamberto, DVM, SVP and President of U.S. Operations for Parnell. “We are proud to offer a solution that supports compassionate, calm, and dignified experiences for dogs and the people who care for them.”

Parnell’s Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution is now available to U.S. veterinary practices via distributor partners. For more information, visit www.parnell.com or contact your local distributor representative.

About Parnell Pet Care

Parnell’s Pet Care portfolio includes PropofolVet Multidose (propofol injectable emulsion), Parnell Brand Dexmedetomidine Hydrochloride Injection, CONTRASED™ (atipamezole hydrochloride), Parnell Brand Isoflurane Inhalation Anesthetic, and Parnell Brand Pentobarbital Sodium and Phenytoin Sodium Euthanasia Solution. To further support veterinary success, Parnell offers the Foundations of Anesthesia & Sedation Certificate Program, an online course providing 10 RACE-approved CE hours. Together, these offerings empower veterinary professionals to deliver confident, high‑quality care through every stage of the patient journey.

About Parnell

Parnell is a veterinary pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. We currently manufacture and market products for companion and production animals in 10 countries. Discover more at www.parnell.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20260303495750/en/

CONTACT: Media Contact:

Angela Kille

Associate Director of Strategic Marketing

[email protected]

913-274-2100

KEYWORD: KANSAS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: CONSUMER HEALTH PETS VETERINARY PHARMACEUTICAL

SOURCE: Parnell

PUB: 03/03/2026 09:11 AM/DISC: 03/03/2026 09:11 AM

http://www.businesswire.com/news/home/20260303495750/en